Developer of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application. Founded in 2010, headquartered in New York City, United States. The company has raised $142.4M in funding at the series b stage. Cresilon operates in the Wound Care, Nanotechnology sectors. The company focuses on Wound Care, Dressing. Notable investors include Paulson Investment, Valued ventures, Hammerstone Capital, PKJ Ventures, IMEX VP Investment Group, Design Technologies, among others.
← All startups
Cresilon
Series BDeveloper of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application. Founded in 2010, headquartered in New York City, United States. The company has raised…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Drugs > Wound Care,
Wound Care > Medical Devices > Therapeutic Devices > Dressing and Wound Closure > Dressing
Institutional investors
Paulson InvestmentValued venturesHammerstone CapitalPKJ VenturesIMEX VP Investment GroupDesign TechnologiesInnovating CapitalDorm Room Fund
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.